Gilead Sciences, Inc. (NASDAQ:GILD) CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 84.51 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The firm has a market capitalization of $110.36 billion, a PE ratio of 9.18 and a beta of 1.19. The company’s 50-day moving average is $76.14 and its 200-day moving average is $69.83.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. During the same period last year, the firm posted $3.08 earnings per share. Analysts forecast that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.46%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/13/robin-l-washington-sells-51820-shares-of-gilead-sciences-inc-gild-stock.html.

Several equities research analysts have issued reports on GILD shares. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Jefferies Group LLC reissued a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 4th. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price objective for the company. in a research report on Wednesday, June 21st. Deutsche Bank AG initiated coverage on shares of Gilead Sciences in a research report on Friday, June 23rd. They issued a “buy” rating and a $79.00 price objective for the company. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a research report on Monday, July 17th. Eleven equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $83.06.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Intl Fcstone Inc. purchased a new stake in Gilead Sciences in the second quarter valued at approximately $1,110,000. Griffin Asset Management Inc. purchased a new stake in Gilead Sciences in the second quarter valued at approximately $1,151,000. Gs Investments Inc. purchased a new stake in Gilead Sciences in the second quarter valued at approximately $577,000. Paradigm Financial Advisors LLC raised its stake in Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares in the last quarter. Finally, RNC Capital Management LLC raised its stake in Gilead Sciences by 1.4% in the second quarter. RNC Capital Management LLC now owns 83,702 shares of the biopharmaceutical company’s stock valued at $5,924,000 after purchasing an additional 1,185 shares in the last quarter. 74.05% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.